ACADIA Pharmaceuticals Inc.
ACAD
Rang in Aktien
#4430
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aktienkurs
$20.42
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$3.52B
Veränderung (1 Tag)
3.13%
Veränderung (1 Jahr)
-3.99%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Kategorie
Healthcare
Umsatz von ACADIA Pharmaceuticals Inc. (ACAD)
Umsatz im Jun 2026 TTM: $1.14B
Laut den aktuellen Finanzberichten von ACADIA Pharmaceuticals Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $1.14B. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $726.44M eine Steigerung gegenüber dem Umsatz im Jahr 2022, der $517.24M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für ACADIA Pharmaceuticals Inc. von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $1.14B | 18.88% |
| 2024 | $957.80M | 31.85% |
| 2023 | $726.44M | 40.45% |
| 2022 | $517.24M | 6.83% |
| 2021 | $484.15M | 9.60% |
| 2020 | $441.76M | 30.28% |
| 2019 | $339.08M | 51.50% |
| 2018 | $223.81M | 79.19% |
| 2017 | $124.90M | 620.68% |
| 2016 | $17.33M | 28,311.48% |
| 2015 | $61.00K | -49.17% |
| 2014 | $120.00K | -89.52% |
| 2013 | $1.15M | -76.67% |
| 2012 | $4.91M | 137.40% |
| 2011 | $2.07M | -95.09% |
| 2010 | $42.14M | 558.46% |
| 2009 | $6.40M | 302.45% |
| 2008 | $1.59M | -78.95% |
| 2007 | $7.56M | -7.11% |
| 2006 | $8.13M | -25.77% |
| 2005 | $10.96M | 137.96% |
| 2004 | $4.60M | -37.60% |
| 2003 | $7.38M | 17.57% |
| 2002 | $6.28M | 68.97% |
| 2001 | $3.71M | -13.87% |
| 2000 | $4.31M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 1,008.71% |
US
|
|
| $2.23B | 95.67% |
US
|
|
| $15.74B | 1,282.73% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 428.81% |
NL
|
